60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Score, Valuation & Financial Research
60 Degrees Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for SXTP
60 Degrees Pharmaceuticals, Inc. currently has a Wall Street Score of 27/100. The stored market price is $0.9. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What 60 Degrees Pharmaceuticals, Inc. does
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine spe
SXTP financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $0.9
- Market capitalization:
- $725K
- Revenue:
- $1.0M
- Net income:
- $-7.6M
- Free cash flow:
- $-7.1M
- Cash:
- $3.3M
- Total debt:
- $152K
- EPS:
- -11.73
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-7.1M, showing cash burn in the current stored period.
- The balance sheet shows $3.3M of cash versus $152K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SXTP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.